GLP-1 Weight Loss Injections: What You Need to Know About Wegovy, Zepbound, and Saxenda

Injectable GLP-1 medications have rapidly become among the most significant developments in obesity treatment in decades, offering clinically verified weight loss for the more than 40% of U.S. adults affected by obesity. These drugs — including semaglutide (Wegovy) and tirzepatide (Zepbound) — work by mimicking a naturally occurring gut hormone that regulates appetite, blood sugar, and digestion, helping patients feel fuller longer, reduce cravings, and slow stomach emptying without the deprivation associated with traditional calorie restriction.

The clinical trial data behind these medications is striking. In the landmark STEP 1 trial, participants on semaglutide lost an average of roughly 15% of their body weight over 68 weeks when combined with lifestyle changes. Tirzepatide performed even more impressively in the SURMOUNT trials, with some participants achieving average weight reductions approaching or exceeding 20% — numbers that represent some of the largest weight-loss results ever documented with prescription medications.

Three injectable medications currently hold FDA approval specifically for weight management: Wegovy (semaglutide, once-weekly), Zepbound (tirzepatide, once-weekly), and Saxenda (liraglutide, daily). Zepbound is notable for targeting both GLP-1 and GIP hormone receptors, a dual-action mechanism that may explain its superior outcomes. Ozempic and Mounjaro — which share the same active ingredients as Wegovy and Zepbound respectively — are FDA-approved for type 2 diabetes but are frequently discussed in the weight-loss context.

Eligibility generally requires a BMI of 30 or higher, or a BMI of 27-plus alongside a weight-related condition such as hypertension, high cholesterol, or type 2 diabetes. The drugs come in prefilled self-injection pens and are typically administered in the abdomen, thigh, or upper arm. Most patients find the small-gauge needles manageable, and weekly dosing schedules improve adherence for many users.

Side effects are real and worth knowing. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are common, especially early in treatment, though they tend to diminish as the body adjusts. More serious but less frequent risks include pancreatitis, gallbladder problems, and severe gastrointestinal events. Beyond weight loss, research has also linked these medications to improvements in blood sugar control, cardiovascular risk markers, and quality of life — reinforcing the growing medical consensus that obesity is a chronic disease requiring comprehensive, often pharmacological, treatment.